Innovation commercialization
Scientific merit is essential, but it does not establish commercial potential by itself. A credible path connects the invention to an unmet need, a defensible advantage, achievable development, and an identifiable industry partner.
The operating principle
It is to determine what is genuinely differentiated, what remains uncertain, which evidence would change the decision, who could realistically act on the opportunity, and what the next value-creating step should be.
Four commercialization decisions
Evaluate the scientific advantage against an unmet need, a real use case, competing solutions, stakeholder behavior, and the evidence required for adoption.
Separate what is known from what is merely promising, then prioritize the technical, clinical, regulatory, reimbursement, manufacturing, IP, and market questions capable of changing the decision.
Identify organizations with strategic fit, frame the invention in industry-relevant terms, and use prospective-partner response to improve both the narrative and the development plan.
Distinguish among licensing, startup formation, collaboration, optioning, additional de-risking, or stopping when the evidence does not support further investment.
Commercialization case files
University technologies, pharmaceutical products, medical devices, and clinical-stage assets each require different evidence. The underlying discipline remains consistent: define the decision, interrogate the uncertainty, and recommend the next value-creating action.
See how 20 stakeholder interviews were converted into tested hypotheses, coded signals, five ranked market pathways, and a three-stage evidence plan.
Which life-science technologies had sufficient commercial and licensing potential to justify active outreach?
ContributionEvaluated technologies, prepared non-confidential technology-marketing materials, identified prospective industry licensees, conducted direct outreach, and developed licensing recommendations in support of university commercialization offices.
Which product-extension route offered the strongest balance of customer value, technical feasibility, defensibility, investment, and speed?
ContributionIdentified an external IP signal, developed multiple formulation and delivery pathways, assessed scientific and manufacturing constraints, and specified the regulatory, market, and technical evidence required before commitment.
Should an early-stage prostate-cancer technology be licensed, advanced through a startup, or de-risked further?
ContributionIntegrated stakeholder discovery, competitive technology analysis, regulatory and reimbursement scenarios, center economics, adoption friction, risk-adjusted valuation, and commercialization-pathway logic.
How likely was the next clinical or regulatory event to succeed, and which new evidence should change that judgment?
ContributionProduced and updated probability-based forecasts across clinical-stage assets, testing biological plausibility, trial design, endpoints, precedent, execution risk, and emerging evidence against resolved outcomes.
Commercialization evidence map
The opportunity becomes credible when different forms of evidence reinforce one another and the remaining gaps are made explicit.
Working across professional boundaries
I contribute scientific, competitive, market, partner, and licensing analysis while working with patent counsel on patentability, prosecution, freedom-to-operate, and legal interpretation. I do not present myself as patent counsel or claim responsibility for legal opinions.
Relevant preparation
The broader practice
This capability complements competitive intelligence, forecasting, market research, valuation, and commercial strategy across the rest of the portfolio.